HuL001

· HuniLife Biotechnology, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for HuL001, covering 2025-09-24 to 2025-10-07. Get the full timeline:

Most recent: Clinical Trial Update: Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients [Phase 1, Phase 2]